진행성 파킨슨병 환자에서 레시곤의 효과 및 안전성에 관한 장기관찰연구 (ELEGANCE)
ELEGANCE - 일상적인 치료에서 진행된 파킨슨병 환자를 대상으로 한 Levodopa-Entacapone-Carbidopa Intestinal Gel(Lecigon®)의 장기적 효과 및 안전성에 대한 비간섭 연구
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.
In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Study design:
Non-interventional study, primary data collection.
No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.
The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.
The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.
Primary Objectives:
- Long-term effectiveness of Lecigon®
- Long-term safety of Lecigon®
Secondary Objectives:
- Patient non-motor symptoms and quality of life
- Healthcare resource utilisation by patients
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
-
Groningen, 네덜란드, 97139713
- University Medical Center Groningen
-
-
-
-
-
Copenhagen, 덴마크, 2400
- Bispebjerg Hospital
-
-
-
-
-
Bad Segeberg, 독일, 23795
- Segeberger Kliniken GmbH Neurologisches Zentrum
-
Beelitz-Heilstätten, 독일, 14547
- Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
-
Berlin, 독일, 10117
- Charité - Universitätsmedizin Berlin
-
Cologne, 독일
- Uniklinik Köln
-
Coppenbrügge, 독일, 31863
- Krankenhaus Lindenbrunn
-
Essen, 독일, 45147
- Klinik für Neurologie - Universitätsklinikum Essen
-
Freiburg im Breisgau, 독일, 79106
- Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
-
Göttingen, 독일, 37075
- Zentrum für Seltene Erkrankungen Göttingen
-
Marburg, 독일, 35043
- Universitätsklinikum Giessen und Marburg
-
Oldenburg, 독일, 26122
- Evangelisches Krankenhaus Oldenburg
-
Osnabrück, 독일, 49076
- Klinikum Osnabrück GmbH Klinik für Neurologie
-
Tübingen, 독일, 72076
- Universitätsklinikum Tübingen
-
Ulm, 독일, 89081
- RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
-
Wolfach, 독일, 77709
- Parkinson-Klinik Ortenau
-
-
-
-
-
Brasov, 루마니아, 500326
- Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
-
Bucharest, 루마니아, 050098
- Bucharest University Emergency Hospital
-
Bucharest, 루마니아
- Fundeni Clinical Institute
-
Bucharest, 루마니아, 011461
- Spitalul Universitar de Urgență Elias
-
Bucharest, 루마니아, 020125
- Colentina Hospital Bucharest
-
Cluj-Napoca, 루마니아, 400347
- County Emergency Hospital Cluj-Napoca
-
Constanța, 루마니아, 900591
- County Clinical Emergency Hospital of Constanta
-
Timișoara, 루마니아, 300723
- Timiş County Emergency Clinical Hospital- Neurology 1
-
Timișoara, 루마니아, 300723
- Timiş County Emergency Clinical Hospital
-
Târgu Mureş, 루마니아, 540136
- Emergency County Hospital Targu Mures
-
-
-
-
-
Bruges, 벨기에, 8000
- AZ Sint-Jan
-
Edegem, 벨기에, 2650
- Antwerp University Hospital
-
Ghent, 벨기에
- Ghent University Hospital
-
Liège, 벨기에
- University Hospital Liege
-
Tournai, 벨기에, 7500
- Centre Hospitalier de Wallonie picarde (Chwapi)
-
-
-
-
-
Sofia, 불가리아, 1113
- Sveti Naum
-
-
-
-
-
Gothenburg, 스웨덴, 413 45
- Sahlgrenska University Hospital
-
Lund, 스웨덴
- Skånes universitetssjukhus Lund
-
Uppsala, 스웨덴, 751 85
- Uppsala university hospital
-
-
-
-
-
Barcelona, 스페인, 08025
- Hospital de la Santa Creu i Sant Pau
-
Madrid, 스페인, 28040
- Hospital Clínico San Carlos
-
Madrid, 스페인, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, 스페인
- Hospital de la Princesa
-
Seville, 스페인, 41013
- Hospital Virgen del Rocio
-
-
-
-
-
Ljubljana, 슬로베니아, 1000
- Department of Neurology, University Medical Centre
-
Maribor, 슬로베니아, 2000
- Univerzitetni klinični center Maribor
-
-
-
-
-
Dublin, 아일랜드, D07 R2WY
- The Dublin Neurological Institute, Mater Hospital
-
Dublin, 아일랜드, D04 T6F4
- St. Vincent's University Hospital
-
-
-
-
-
Graz, 오스트리아, 8036
- Universitätsklinik für Neurologie, Medizinische Universität Graz
-
Hermagor, 오스트리아, 9620
- Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
-
Innsbruck, 오스트리아, 6020
- Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
-
Linz, 오스트리아, 4020
- Kepler Universitätsklinikum
-
-
-
-
-
Brno, 체코
- Masaryk university
-
Olomouc, 체코
- Fakultní nemocnice Olomouc
-
-
-
-
-
Osijek, 크로아티아, 31000
- UHC Osijek, J. Klinici za neurologiju
-
Rijeka, 크로아티아
- University Hospital Centre Rijeka (KBC Rijeka)
-
Zagreb, 크로아티아, 10000
- University Hospital Centre (KBC Zagreb)
-
Zagreb, 크로아티아, 10000
- Klinička bolnica Dubrava
-
-
-
-
-
Budapest, 헝가리
- Semmelweis Egyetem Neurológiai Klinika Budapest
-
Pécs, 헝가리, 7623
- Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
-
Szeged, 헝가리, 6725
- SZTE Szent-Györgyi Albert Klinikai Közpon
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Treating physician's normal patient pool
설명
Inclusion Criteria:
- Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
- Patients or legal representative must have signed informed consent to participate in the study
- Patients are not taking part in another clinical (interventional) study at the same time
Exclusion Criteria:
- Patients with contraindications as defined in the current version of the SmPC for Lecigon®
- Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
- Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications) |
24 months
|
|
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living) |
24 months
|
|
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses |
24 months
|
|
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected |
24 months
|
|
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I) |
24 months
|
|
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C) |
24 months
|
|
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
기간: 24 months
|
To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item. |
24 months
|
|
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
기간: 24 months
|
To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected |
24 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS) |
24 months
|
|
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2) |
24 months
|
|
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living) |
24 months
|
|
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39) |
24 months
|
|
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit |
24 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- NIS-MA-2020-02
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .